Allarity Therapeutics (ALLR) EBITDA (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly EBITDA came in at -$2.7 million in Q1 2026, up 11.46% YoY from -$2.4 million in Q1 2025, and up 7.88% on a QoQ basis from -$2.9 million in Q4 2025.
Allarity Therapeutics (ALLR) EBITDA (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of EBITDA data on file, last reported at -$2.7 million in Q1 2026.
- Quarterly EBITDA rose 11.46% year-over-year to -$2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.3 million (up 52.92% YoY) and the FY2025 annual result came in at -$12.6 million, up 53.73% from the prior year.
- EBITDA grew to -$2.7 million in Q1 2026, from -$2.9 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$2.5 million in Q3 2025 to a low of -$18.3 million in Q1 2022.
- A 5-year average of -$5.5 million and a median of -$4.2 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA slumped 643.66% — and 2023, when it soared 79.97%.
- Tracing ALLR's EBITDA over 5 years: stood at -$6.8 million in 2022, then gained by 27.72% to -$4.9 million in 2023, then slumped by 49.97% to -$7.3 million in 2024, then jumped by 60.12% to -$2.9 million in 2025, then increased by 7.88% to -$2.7 million in 2026.
- The last three EBITDA figures came in at -$2.7 million (Q1 2026), -$2.9 million (Q4 2025), and -$2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Allarity Therapeutics | 23.23 Mn | 23.23 Mn | - | -2.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.69 Mn |
| Dec 31, 2025 | -2.92 Mn |
| Sep 30, 2025 | -2.52 Mn |
| Jun 30, 2025 | -4.13 Mn |
| Mar 31, 2025 | -3.04 Mn |
| Dec 31, 2024 | -7.32 Mn |
| Sep 30, 2024 | -12.31 Mn |
| Jun 30, 2024 | -3.37 Mn |
| Mar 31, 2024 | -4.24 Mn |
| Dec 31, 2023 | -4.88 Mn |
| Sep 30, 2023 | -4.43 Mn |
| Jun 30, 2023 | -4.16 Mn |
| Mar 31, 2023 | -3.67 Mn |
| Dec 31, 2022 | -6.75 Mn |
| Sep 30, 2022 | -4.56 Mn |
| Jun 30, 2022 | -4.84 Mn |
| Mar 31, 2022 | -18.31 Mn |
| Dec 31, 2021 | -15.74 Mn |
| Sep 30, 2021 | -3.97 Mn |
| Jun 30, 2021 | -4.38 Mn |